Crossmark

Comparison of fully-automated radiosyntheses of [11C]erlotinib for preclinical and clinical use starting from in target produced [11C]CO2 or [11C]CH4

Crossref DOI link: https://doi.org/10.1186/s41181-018-0044-1

Published Online: 2018-05-30

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Philippe, Cécile

Mairinger, Severin

Pichler, Verena

Stanek, Johann

Nics, Lukas

Mitterhauser, Markus

Hacker, Marcus

Wanek, Thomas

Langer, Oliver

Wadsak, Wolfgang http://orcid.org/0000-0003-4479-8053
Funding

Funding for this research was provided by:

Austrian Science Fund (F 3513-B20, KLI 480-B30, I 1609-B24)

Lower Austria Corporation for Research and Education (LS12-006, LS15-003)
License Information

Text and Data Mining valid from 2018-05-30
More Information

Article History

Received: 9 March 2018

Accepted: 1 May 2018

First Online: 30 May 2018

Ethics approval and consent to participate

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.